sulfasalazine has been researched along with Hyperplasia in 6 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
Hyperplasia: An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Lentinan decreased the number of tumours, inflammatory cell infiltration, atypical hyperplasia and nuclear atypia in azoxymethane/DSS-induced CAC model." | 7.91 | Therapeutic effects of lentinan on inflammatory bowel disease and colitis-associated cancer. ( Chen, S; Jing, X; Li, M; Liu, H; Liu, Y; Sun, B; Sun, T; Tian, Y; Wang, H; Yang, C; Zhang, Q; Zhao, J; Zhao, Y; Zong, S, 2019) |
| " Lentinan decreased the number of tumours, inflammatory cell infiltration, atypical hyperplasia and nuclear atypia in azoxymethane/DSS-induced CAC model." | 3.91 | Therapeutic effects of lentinan on inflammatory bowel disease and colitis-associated cancer. ( Chen, S; Jing, X; Li, M; Liu, H; Liu, Y; Sun, B; Sun, T; Tian, Y; Wang, H; Yang, C; Zhang, Q; Zhao, J; Zhao, Y; Zong, S, 2019) |
| "Susalimod was extensively excreted via the bile in all animal species, > or =90%, mainly as non-conjugated parent compound." | 1.30 | Extensive biliary excretion of the sulfasalazine analogue, susalimod, but different concentrations in the bile duct in various animal species correlating to species-specific hepatobiliary toxicity. ( Andersson, S; Gunnarsson, K; Odell, ML; Påhlman, I; Wilén, M, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Y | 1 |
| Zhao, J | 1 |
| Zhao, Y | 1 |
| Zong, S | 1 |
| Tian, Y | 1 |
| Chen, S | 1 |
| Li, M | 1 |
| Liu, H | 1 |
| Zhang, Q | 1 |
| Jing, X | 1 |
| Sun, B | 1 |
| Wang, H | 1 |
| Sun, T | 1 |
| Yang, C | 1 |
| Kim, JY | 1 |
| Cho, HJ | 1 |
| Sir, JJ | 1 |
| Kim, BK | 1 |
| Hur, J | 1 |
| Youn, SW | 1 |
| Yang, HM | 1 |
| Jun, SI | 1 |
| Park, KW | 1 |
| Hwang, SJ | 1 |
| Kwon, YW | 1 |
| Lee, HY | 1 |
| Kang, HJ | 1 |
| Oh, BH | 1 |
| Park, YB | 1 |
| Kim, HS | 1 |
| Gallais, V | 1 |
| Grange, F | 1 |
| De Bandt, M | 1 |
| Crickx, B | 1 |
| Belaïch, S | 1 |
| Spodaryk, M | 1 |
| Mrukowicz, J | 1 |
| Stopyrowa, J | 1 |
| Czupryna, A | 1 |
| Kowalska-Duplaga, K | 1 |
| Fyderek, K | 1 |
| Miezynski, W | 1 |
| Påhlman, I | 1 |
| Andersson, S | 1 |
| Gunnarsson, K | 1 |
| Odell, ML | 1 |
| Wilén, M | 1 |
| Lafeuillade, A | 1 |
| Bolla, G | 1 |
| Horschowski, N | 1 |
| Fossat, C | 1 |
| David, M | 1 |
| Salvator, V | 1 |
| Schiano, A | 1 |
6 other studies available for sulfasalazine and Hyperplasia
| Article | Year |
|---|---|
Therapeutic effects of lentinan on inflammatory bowel disease and colitis-associated cancer.
Topics: Animals; Anti-Inflammatory Agents; Anticarcinogenic Agents; Azoxymethane; Carcinoembryonic Antigen; | 2019 |
Sulfasalazine induces haem oxygenase-1 via ROS-dependent Nrf2 signalling, leading to control of neointimal hyperplasia.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Apoptosis; Carotid Artery Diseases; | 2009 |
[Salazosulfapyridine-induced eruption. Pustular erythroderma and pseudo-lymphomatous syndrome: 2 cases].
Topics: Adult; Dermatitis, Exfoliative; Diagnosis, Differential; Drug Eruptions; Eosinophilia; Female; Human | 1994 |
Severe intestinal nodular lymphoid hyperplasia in an infant.
Topics: Barium Sulfate; Colon; Duodenum; Enema; Enteral Nutrition; Humans; Hyperplasia; Infant; Intestinal P | 1995 |
Extensive biliary excretion of the sulfasalazine analogue, susalimod, but different concentrations in the bile duct in various animal species correlating to species-specific hepatobiliary toxicity.
Topics: Animals; Area Under Curve; Benzoates; Bile; Bile Ducts; Bilirubin; Dogs; Dose-Response Relationship, | 1999 |
[Lymphadenopathy due to sulfasalazine in rheumatoid polyarthritis].
Topics: Aged; Arthritis, Rheumatoid; Female; Humans; Hyperplasia; Lymphatic Diseases; Sulfasalazine | 1989 |